BI 99179
BI 99179 is a selective small molecule inhibitor suitable for the in vivo validation of type 1 fatty acid synthase (FAS) as a therapeutic target for lipid metabolism-related disorders (lipid metabolism disorder) which has been discovered…
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
BI 99179 is a selective small molecule inhibitor suitable for the in vivo validation of type 1 fatty acid synthase (FAS) as a therapeutic target for lipid metabolism-related disorders (lipid metabolism disorder) which has been discovered by Boehringer Ingelheim.
Further reading
Alexandra D'Arcangelis, John Bajor, Kimberly Campbell, Helen Knaggs. U.S. Patent 53631, 2005.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1329234632 under CC BY-SA 4.0; modifications have been made.